Literature DB >> 2340851

Conversion of drug-induced SLE-syndrome by the vasodilating agent cadralazine.

H Mulder1.   

Abstract

The disappearance of a drug induced SLE syndrome in a 43 year old man, was described. He replaced antihypertensive agent hydralazine by an other vasodilating agent cadralazine.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2340851     DOI： 10.1007/bf00315036

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  4 in total

1.  Cadralazine did not produce the SLE-syndrome when hydralazine did.

Authors:  O K Andersson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 2.  Drug-induced lupus: clinical spectrum and pathogenesis.

Authors:  J J Cush; E A Goldings
Journal:  Am J Med Sci       Date:  1985-07       Impact factor: 2.378

3.  The lupus syndrome induced by hydralazine: a common complication with low dose treatment.

Authors:  H A Cameron; L E Ramsay
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

4.  Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.

Authors:  M Catalano; J Parini; M Romano; A Libretti
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953
  4 in total
  1 in total

Review 1.  Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  D McTavish; R A Young; S P Clissold
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.